In a recent study by the activist-funded JAMA Network, researchers erroneously “determined” that the price of diabetes medicines, like insulins, SGLT2 inhibitors, and GLP-1 agonists, were “too high.” Unsurprisingly, they touted price controls as a policy tool for governments to use to reduce these costs. This study uses cost-based pricing to assess affordability – a fundamentally flawed […] Read this story
